Therapies that block PD-L1/PD-1 interaction between cancer cells and T cells thus promoting anti-tumor immunity have shown remarkable clinical efficacy in the treatment of a variety of malignant diseases [2–4]. The gene discussed is PDCD1; the disease is cancer.